Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

Executive Summary

Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency

You may also be interested in...



FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.

FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.

Chart: Obesity: Three New Drug Candidates Promise A New Dawn

Arena is positioning its pending anti-obesity NME lorcaserin as the cure for the obesity market hangover induced by the troublesome side effect profiles associated with earlier Rx weight loss products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel